Employees: 925
Size Zylox-Tonbridge Medical Technology (2190.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $768M, the 645th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$17.90 on 18 Nov 2026.
Performance Over six months the shares fell 15.8%, against -12.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 39.3% over the last twelve months (peer median +10.2%); the operating margin is 24.7% (peer median 11.4%).
Valuation It trades at 14.4× forward earnings against a peer median of 20.2× (3rd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +106%, so the hurdle is -102 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.6 points above its cost of capital (8.8% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.35B | HK$1.15B | HK$848M | HK$583M | HK$389M |
| Revenue growth | — | +35% | +45% | +50% | — |
| Gross profit | HK$963M | HK$806M | HK$587M | HK$400M | HK$271M |
| EBITDA | HK$380M | HK$260M | HK$110M | -HK$131M | -HK$238M |
| Net income | HK$342M | HK$265M | HK$109M | -HK$87.0M | -HK$132M |
| Free cash flow | HK$417M | HK$299M | -HK$20.2M | -HK$104M | -HK$262M |
| Capital expenditure | HK$104M | HK$121M | HK$207M | HK$211M | HK$169M |
| Total debt | n/a | HK$70.9M | HK$96.7M | HK$61.5M | HK$15.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2190.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.7% | -8.5% | 8th lowest of 21 |
| 6-month return | -15.8% | -12.4% | 11th highest of 21 |
| Distance from 52-week high | -36.1% | -40.6% | 9th highest of 21 |
| Revenue growth (TTM) | +39.3% | +10.2% | 4th highest of 21 |
| Operating margin | 24.7% | 11.4% | highest of 21 |
| Forward P/E | 14.4× | 20.2× | 3rd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 3.8% | 8.8% | 6th least demanding of 13 |
| Growth delivered (Del g) | +105.8% | +12.8% | highest of 13 |
| Hurdle (Req g minus delivered) | -102.0 pp | -3.7 pp | least demanding of 13 |
| ROIC minus cost of capital | +3.6 pp | -2.5 pp | 5th highest of 21 |
| EV / EBITDA | 12.7× | 14.7× | 4th cheapest of 9 |
| Net debt / EBITDA | -3.3× | 0.2× | 3rd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 14.4× | 3.8% | +105.8% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 19.9× | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 19.8× | 9.6% | +15.5% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | n/a | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 11.5× | 21.3% | +13.2% |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 421.0× | 7.9% | -10.2% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | n/a | n/a | n/a |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | n/a | n/a | n/a |
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 60.0× | 27.9% | +9.9% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | n/a | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 16.2× | -1.9% | +11.8% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 20.5× | 20.3% | -0.2% |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 9.8× | -10.8% | +12.4% |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | n/a | n/a | n/a |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 18.7× | -1.5% | +15.6% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 27.4× | 17.1% | +24.2% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 20.0× | -6.7% | -15.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 20.7× | 20.0% | +21.4% |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 25.8× | 2.7% | +20.9% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | n/a | n/a | n/a |
| Caina Technology 301122.SZ | China | $721M | +36% | +61% | 0% | 55.4× | n/a | n/a |